Drug-device combination market to hit $249.3 billion by 2030

The global drug-device combination market is projected to grow from $144.22 billion in 2025 to $249.33 billion by 2030, according to a new Business Research Company report. Growth is being driven by chronic disease cases, self-administration devices, and demand for more precise, personalized drug delivery.

Why it matters: - Drug-device combination products are becoming more important as healthcare shifts toward targeted treatment, home delivery and personalized medicine. - The market’s projected climb to $249.33 billion by 2030 points to sustained demand for technologies that can improve dosing precision, adherence and patient outcomes. - Chronic disease growth is a major demand driver because long-term conditions often require continuous and carefully managed therapy.

What happened: - The Business Research Company released its Drug Device Combination Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The market is estimated at $144.22 billion in 2025 and is projected to rise to $161.48 billion in 2026. - The report forecasts the market will reach $249.33 billion by 2030, implying an 11.5% CAGR over the forecast period. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Drug-device combination products pair a medical device with a pharmaceutical agent for therapeutic or diagnostic use. - The products are used for local administration, targeted delivery and tailored therapy. - The report says the products are physically and chemically integrated and packaged as a single unit. - The market’s recent growth has been supported by rising chronic disease incidence, broader use of injectable therapies, biologics adoption, self-administration devices and more regulatory approvals for combination products. - Future growth is expected to come from personalized medicine, investment in digital therapeutics, home-based drug delivery systems, connected medical devices and precision drug targeting. - Emerging trends include smart drug delivery devices, patient-centric combination products, digital monitoring integration, targeted therapy delivery platforms and personalized treatment solutions. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 edition adds market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The Business Research Company offers a free sample and the full report here and here. - The press release also listed contact details for Saumya Sahay at The Business Research Company.

Between the lines: - The report frames drug-device combinations as a core part of the move toward more precise, convenient and data-enabled care. - The growth forecast suggests the category is expanding beyond specialist applications into broader chronic disease management and at-home treatment. - The regional outlook points to mature demand in North America and faster momentum in Asia-Pacific, which may reflect different stages of healthcare adoption and investment.

What's next: - The market is expected to keep expanding as drug delivery devices become smarter and more connected. - Continued uptake of personalized medicine and home-based treatment could further widen the addressable market through 2030. - Manufacturers and developers are likely to focus on targeted delivery platforms and monitoring features as key differentiators.

The bottom line: - Drug-device combination products are moving from a niche category to a major healthcare growth market, with chronic disease pressure and precision treatment needs driving the next phase of expansion.